NCT00058305View on ClinicalTrials.gov

Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

December 31, 2007

Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaSplenic Marginal Zone Lymphoma
Interventions
DRUG

bryostatin 1

Given IV

DRUG

vincristine sulfate

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

44106

Case Western Reserve University, Cleveland

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00058305 - Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation | Biotech Hunter | Biotech Hunter